title: Realgar-induced differentiation is associated with MAPK pathways in HL-60 cells.
abstract: The clinical efficacy and safety of realgar (arsenic sulfide, As(4)S(4)) in the treatment of acute promyelocytic leukemia in China have given rise to an upsurge in research on the underlying mechanism. We prepared realgar nanoparticles (RNPs) to examine their effect on the differentiation of HL-60 cells. Treatment with RNPs at 6 microM for 72 h induced cell differentiation that was assessed by morphological change, NBT reductive ability, and elevation of CD11b expression at both mRNA and protein levels. The RNP-induced differentiation was synergized, enhanced and suppressed by the inhibition of p38 MAPK, JNK and ERK pathways, respectively. Our findings demonstrate that MAPK signaling pathways are closely related to the RNP-induced differentiation in HL-60 cells.
authors.affiliation: Department of Chemical Biology, Peking University School of Pharmaceutical Sciences, 38 Xueyuan Road, Beijing 100083, PR China.
authors.forename: Nan
authors.initials: N
authors.lastname: Wang
authors.forename: Li-Wen
authors.initials: LW
authors.lastname: Wang
authors.forename: Bao-Di
authors.initials: BD
authors.lastname: Gou
authors.forename: Tian-Lan
authors.initials: TL
authors.lastname: Zhang
authors.forename: Kui
authors.initials: K
authors.lastname: Wang
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001152:Arsenicals / Q000494:pharmacology* / Q000627:therapeutic use; D018845:CD11 Antigens / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects* / Q000502:physiology; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D018922:HL-60 Cells; D006801:Humans; D048031:JNK Mitogen-Activated Protein Kinases / Q000187:drug effects / Q000378:metabolism; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000201:enzymology* / Q000503:physiopathology; D020935:MAP Kinase Signaling System / Q000187:drug effects* / Q000502:physiology; D048052:Mitogen-Activated Protein Kinase 3 / Q000187:drug effects / Q000378:metabolism; D053758:Nanoparticles / Q000627:therapeutic use; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D013440:Sulfides / Q000494:pharmacology* / Q000627:therapeutic use; D048051:p38 Mitogen-Activated Protein Kinases / Q000187:drug effects / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D018845:CD11 Antigens; D012333:RNA, Messenger; D013440:Sulfides; C058317:arsenic disulfide; D048031:JNK Mitogen-Activated Protein Kinases; D048052:Mitogen-Activated Protein Kinase 3; D048051:p38 Mitogen-Activated Protein Kinases